Industry And Academic Pros Attract More Than 150 Participants At Aptuit Science Day In Verona, Italy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry And Academic Pros Attract More Than 150 Participants At Aptuit Science Day In Verona, Italy


Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, expressed appreciation to guests and presenters who participated in the second annual Science Day Event at The Aptuit Center for Drug Discovery & Development in Verona, Italy on May 16, 2012. "Once again, we were able to share a lively exchange of ideas in response to the insightful presentations delivered by distinguished members of the industry and academia," he said.

Aptuit hosted the free event which focused on "Challenging Current Paradigms in Early Drug Development."

"For the event, we engaged prominent and highly respected scientists, knowledgeable in early drug development, to deliver presentations during our full day’s agenda. Several of the speakers spoke of recent and innovative approaches that reduce the time, costs and attrition of drug development – the issues that are at the heart of our common concerns and interests," said Mark Hembarsky, Vice President and Site Director at Verona.

Last year Aptuit initiated the Aptuit Scientific Symposium at their Verona, Italy location. From this site, Aptuit offers a fully integrated offering of drug discovery and development services.

Referring to the 2011 Science Day, Mr. Needleman concluded, "Since the May 16, 2012 event repeated last year’s great success, we are looking forward to another Aptuit hosted symposium of its kind. Those who attended found it a valuable experience, and it provided the opportunity for our guests to have a firsthand encounter with Aptuit people with heads for science and hearts for service."

Details about the Science Day, including copies of the presentations, are available at the Aptuit Verona microsite: www.aptuit.com/Verona.

For press information, please contact Maria Garvey at Delfino Marketing either by phone at 914-747-1400 or by email: maria@delfino.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here